Department of Neurosurgery, The First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Medical School of Chinese PLA, Beijing, China.
Sci Rep. 2022 Feb 28;12(1):3343. doi: 10.1038/s41598-022-07287-0.
Diffuse and multi-lobes involved glioma (DMG) is a rare disease, and the aim of this study was to assess the role of multimodal-assisted surgical resection of tumours combined with chemoradiotherapy and identify prognosis. Clinical data were collected from 38 patients with a diagnosis of DMG. Nineteen patients received multimodal-assisted surgical resection of tumours combined with chemoradiotherapy, and another 19 patients underwent chemoradiotherapy alone after stereotactic puncture biopsy. The clinical characteristics, magnetic resonance imaging (MRI) findings, histopathological diagnosis, progression-free survival, and overall survival of DMG patients were retrospectively analysed. Twenty-six males and 12 females were included, and the age of the participants ranged from 10 to 80 years (46.34 ± 15.61). The median overall survival in our study was 25 months, and the progression-free survival was 17 months. The extent of resection was 50.10-73.60% (62.54% ± 7.92%). The preoperative and the postoperative KPS score of the patients in the operation group showed no statistically significant difference. The results of logistic regression demonstrated that overall survival was positively associated with operative treatment + chemoradiotherapy (p = 0.003) but negatively associated with age and corpus callosal involvement (p = 0.028 and 0.022, respectively). Kaplan-Meier analyses showed that those who underwent surgical treatment had a significant progression-free and overall survival benefit compared to those who did not undergo surgical treatment (log-rank test; p = 0.011 and 0.008, respectively). Older age and involvement of the corpus callosum represent a poor prognosis in DMG patients. Multimodal-assisted surgical resection of tumours combined with chemoradiotherapy might be a treatment option for DMG. Further research is needed to obtain the clear evidence of the effect of surgical treatment.
弥漫性多叶脑胶质瘤(DMG)是一种罕见疾病,本研究旨在评估多模态辅助手术切除肿瘤联合放化疗的作用,并确定其预后。收集了 38 例 DMG 患者的临床资料。19 例患者接受多模态辅助手术切除肿瘤联合放化疗,另 19 例患者经立体定向穿刺活检后仅接受放化疗。回顾性分析 DMG 患者的临床特征、磁共振成像(MRI)表现、组织病理学诊断、无进展生存期和总生存期。患者中男性 26 例,女性 12 例,年龄 10-80 岁,平均年龄(46.34±15.61)岁。中位总生存期为 25 个月,无进展生存期为 17 个月。肿瘤切除范围为 50.10-73.60%(62.54%±7.92%)。手术组患者术前和术后 KPS 评分无统计学差异。Logistic 回归分析结果显示,总生存期与手术治疗+放化疗呈正相关(p=0.003),与年龄和胼胝体受累呈负相关(p=0.028 和 0.022)。Kaplan-Meier 分析显示,与未行手术治疗的患者相比,行手术治疗的患者无进展生存期和总生存期明显延长(log-rank 检验;p=0.011 和 0.008)。年龄较大和胼胝体受累是 DMG 患者预后不良的因素。多模态辅助手术切除肿瘤联合放化疗可能是 DMG 的一种治疗选择。需要进一步的研究来获得手术治疗效果的明确证据。